ISC 2026 | Reflecting on the results of OCEANIC-STROKE: a paradigm shift in secondary stroke prevention
Valeria Caso, MD, PhD, FESO, Santa Maria Della Misericordia Hospital, University of Perugia, Perugia, Italy, reflects on the results of the OCEANIC-STROKE trial (NCT05686070), which she believes represents a paradigm shift in secondary stroke prevention. This interview took place at the 2026 International Stroke Congress (ISC), held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We can only be happy. 26% of risk reduction is beyond all expectations. So this will be a paradigm shift also for better secondary stroke prevention for our patients finally after years. So we started in ’96 with aspirin after stroke. Then there was something. We had the dual antiplatelets. So we were going down with the risk, but still we were not there. And now we have something, again, that really reduced massively the risk of having a second stroke...
We can only be happy. 26% of risk reduction is beyond all expectations. So this will be a paradigm shift also for better secondary stroke prevention for our patients finally after years. So we started in ’96 with aspirin after stroke. Then there was something. We had the dual antiplatelets. So we were going down with the risk, but still we were not there. And now we have something, again, that really reduced massively the risk of having a second stroke. And I think this is absolutely where we need to work on and there cannot be a delay in the introduction of the drug worldwide.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
